DISCLOSURE: This site receives compensation from featured companies, which may influence rankings. Read Advertising Disclosure
Compounded Semaglutide
compoundedNot FDA-approved; produced under 503A/503B compounding exemptions during branded drug shortage. FDA enforcement is increasing with 80+ warning letters issued to compounders as of early 2026.
Est. Cost
$179-$299/mo
/month
Compounded semaglutide is a version of the GLP-1 medication produced by compounding pharmacies rather than the brand-name manufacturer Novo Nordisk. It has historically been available at a significantly lower cost than branded Wegovy, making it an attractive option for patients without insurance coverage. However, the regulatory landscape is shifting rapidly — the FDA has ramped up enforcement actions, branded prices have dropped, and the long-term availability of compounded versions is increasingly uncertain.
Dosage Format
Weekly subcutaneous injection; dosing protocols vary by compounding pharmacy
Type
Compounded
Best For
Cost-conscious patients who understand the regulatory risks and want GLP-1 therapy at a lower price point
Key Benefit
Compounded semaglutide has been a lower-cost alternative to branded Wegovy, but the FDA has issued over 80 warning letters to compounding pharmacies as of early 2026, and the market is shrinking as branded prices drop and shortages resolve.
Where to Get Compounded Semaglutide
Compare providers offering compounded semaglutide — ranked by our editorial team
Henry Meds
One of the larger compounded GLP-1 providers; verify current availability as FDA enforcement actions evolve
$179-$249/mo
/month
ShedRx
Offers compounded semaglutide with provider consultations; check current regulatory status before enrolling
$199-$299/mo
/month
Fridays
Among the lowest-priced compounded options; availability may be limited as market conditions shift
$117-$199/mo
/month
How Compounded Semaglutide Works
Compounded semaglutide is intended to work through a GLP-1 receptor agonist, targeting appetite regulation centers in the brain and slowing gastric emptying. However, because compounded formulations are not subject to the same manufacturing standards as FDA-approved drugs, there may be variability in potency, purity, and stability between batches and pharmacies. Some compounded versions use semaglutide salt forms (such as semaglutide sodium) rather than the exact base form used in Wegovy, and the clinical equivalence of these formulations has not been formally established.
Side Effects
Common
- • Nausea
- • Diarrhea
- • Vomiting
- • Constipation
- • Abdominal pain
- • Injection site reactions
- • Headache
Serious (Rare)
- • Potential quality and potency variability between compounding pharmacies
- • Pancreatitis (rare)
- • Gallbladder problems
- • Kidney injury from dehydration
- • Risk of contamination or dosing errors from non-standardized manufacturing
- • Thyroid C-cell tumor risk (same class warning as branded semaglutide)
Who Is Eligible
Eligibility criteria are generally similar to branded semaglutide: adults with a BMI of 30 or greater, or 27 or greater with weight-related conditions. However, patients should be aware that compounded medications carry additional risks related to quality variability and uncertain regulatory status. Some telehealth providers may be transitioning patients away from compounded options as branded alternatives become more affordable.